Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
  • Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study
     
  • Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseases
     
  • Sandoz is committed to supporting healthcare professionals to advance patient care and improve access to medicines sustainably and affordably
     

Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …

/by